

November 03, 2025

To
The Corporate Relations Department,
BSE Limited,
Company Code No. **526301**

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on November 03, 2025.

We hereby inform you that, the Board of Directors in their meeting held today i.e. on **Monday, November 03, 2025**, has inter-alia considered and noted/approved the following matters: -

1. Un-audited Standalone and Consolidated Financial Results of the Company for the Second Quarter and Half-Year ended September 30, 2025.

A signed copy of the above Financial Results along with Limited Review Report issued by the Statutory Auditors thereon under Regulation 33 of the Listing Regulations are enclosed to this letter.

2. The receipt of the certified true copy of the order dated 13th October 2025 passed by Hon'ble National Company Law Tribunal, Hyderabad Bench, Hyderabad ("NCLT") sanctioning the scheme of Amalgamation ("Scheme") of Medinova Diagnostic Services Limited ("Transferor Company") with and into Vijaya Diagnostic Centre Limited ("Transferee Company") and its shareholders and creditors.
3. **Effective Date:** - The Scheme shall be effective on the date on which the certified true copy of the order passed by NCLT sanctioning the Scheme will be filed by both the Transferor and Transferee companies with the Registrar of Companies, Hyderabad ("ROC"). The effective date of the Scheme shall be intimated separately to the stock exchanges in due course.
4. **Appointed Date:** - The appointed date as per the Scheme is 01st April 2024.

5. **Share Exchange Ratio:** - The share exchange ratio as per the Scheme is as follows:

“For every 22 (Twenty-Two) equity shares of face value of INR 10 (INR Ten only) each fully paid held in the Transferor Company as on the Record Date, the equity shareholders of the Transferor Company shall be issued 1 (One) equity share of face value of INR 1 (INR One only) each fully paid in the Transferee Company.”

6. **Record Date:** - In consultation with the Transferee Company the record date for determining the shareholders of the Transferor Company to whom the shares in Transferee Company would be issued under the Scheme is **Tuesday, 25th November 2025.**

The Meeting commenced at 10:30 A.M. (IST) and concluded at 12:00 Noon (IST).

Kindly take the same on record.

Thanking You.

For **Medinova Diagnostic Services Limited**

Hansraj Singh
Company Secretary & Compliance Officer
M. No. F11438

M.ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

**Review Report to the Board of Directors
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Services Limited (the "Company") for the quarter ended 30th September, 2025 and year to date results for the period 1st April, 2025 to 30th September, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

5. The Scheme of Amalgamation of the Company, with and into the Holding Company "Vijaya Diagnostic Centre Limited" with effect from 01st April, 2024, was approved by its shareholders on 25th April, 2025. The Scheme was also approved by the Hon'ble National Company Law Tribunal, Hyderabad vide its order dated 13th October, 2025. The Scheme will be effective upon filing of the certified true copy of the NCLT order with the Registrar of Companies, Hyderabad.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

MADHURI
CHIMALGI

Digitally signed by
MADHURI CHIMALGI
Date: 2025.11.03
11:45:26 +05'30'

Madhuri Chimalgi
Partner
M No: 235955

UDIN: 25235955BOGRSW4480

Place: Secunderabad
Date: 3rd November, 2025



MEDINOVA DIAGNOSTIC SERVICES LIMITED
CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Amcerpet, Hyderabad - 500 016.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th September, 2025

Sl. No.	Particulars	Quarter Ended			Six months ended		(Rs. in Lakhs)
		30.09.2025 (Unaudited)	30.06.2025 (Unaudited)	30.09.2024 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	Year Ended 31.03.2025 (Unaudited)
1	Income:						
	(a) Revenue from Operations	188.60	207.83	197.70	396.43	383.21	754.81
	(b) Other Income	1.20	2.89	2.16	4.09	4.15	12.06
	Total Income	189.80	210.72	199.86	400.52	387.36	766.87
2	Expenses						
	(a) Cost of Materials Consumed	11.60	11.52	13.74	23.12	30.28	50.07
	(b) Employee Benefits Expense	39.04	38.13	41.96	77.17	83.62	163.74
	(c) Testing Fees	22.47	22.06	19.84	44.53	34.86	83.40
	(d) Finance Costs	10.51	11.85	12.60	22.36	25.07	50.00
	(e) Depreciation and amortisation expenses	3.32	3.45	3.59	6.77	6.74	14.14
	(f) Other Expenses	63.13	75.70	73.79	138.83	150.60	286.10
	Total Expenses	150.07	162.71	165.52	312.78	331.17	647.45
3	Profit before Tax [1-2]	39.73	48.01	34.34	87.74	56.19	119.42
4	Tax Expense						
	(a) Current Tax	8.97	11.10	8.91	20.07	11.01	19.66
	(b) Earlier Year's Tax	-	-	-	-	-	0.42
	(c) Deferred Tax	7.00	1.28	0.66	8.28	3.78	10.42
	Total tax expense	15.97	12.38	9.57	28.35	14.79	30.50
5	Profit/Loss for the period (3-4)	23.76	35.63	24.77	59.39	41.40	88.92
6	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss :						
	i) Remeasurement of defined benefit plans	(0.72)	(0.73)	-	(1.45)	-	(2.64)
	ii) Income tax relating to above	0.18	0.18	-	0.36	-	0.67
7	Total Comprehensive Income for the period (5+6)	23.22	35.08	24.77	58.30	41.40	86.95
8	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)						
	a) Basic (Rs.)	0.24	0.36	0.25	0.59	0.41	0.89
	b) Diluted (Rs.)	0.24	0.36	0.25	0.59	0.41	0.89

Notes

- The above Standalone financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 03 November 2025. The above results are subject to audit by the statutory auditors of the company. An unmodified report has been issued by them thereon.
- The Company has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- The Board of Directors of the Company, at its meeting held on 26 June 2024, approved a Scheme of Amalgamation ("the Scheme") under which Medinova Diagnostic Services Limited ("Transferor Company") would get merged with Vijaya Diagnostic Centre Limited ("Transferee Company") with effect from 01 April 2024 ("the Appointed Date"), pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and the rules made thereunder. The Scheme was approved by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), vide its order dated 13 October 2025. The Scheme will be effective upon filing of the certified true copy of the NCLT order with the Registrar of Companies, Hyderabad. Upon the scheme being effective the transferor company shall stand automatically dissolved without winding-up and the offices of the Directors, Key Managerial Personnel and Statutory Auditors will stand vacated.

Place: Hyderabad
Date: 03 November 2025

For Medinova Diagnostic Services Limited
SUNIL CHANDRA
KONDAPALLY
Sunil Chandra Kondapally
Managing Director
DIN 01409332

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Unaudited Standalone Balance Sheet as at September 30, 2025

(Rs. in Lakhs)

SI No.	Particulars	As at 30.09.2025 (Unaudited)	As at 31.03.2025 (Audited)
	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	124.62	129.45
	(b) Intangible assets	1.78	2.68
	(c) Financial assets		
	(i) Investments	296.82	296.82
	(ii) Other financial assets	24.98	30.22
	(d) Deferred tax assets (net)	32.45	40.38
	(e) Non-current tax assets (net)	9.70	11.89
	Total non-current assets	490.35	511.44
II	Current assets		
	(a) Inventories	9.54	11.63
	(b) Financial assets		
	(i) Trade receivables	40.11	47.71
	(ii) Cash and cash equivalents	108.27	88.08
	(iii) Other financial assets	6.54	0.91
	(c) Other current assets	4.33	3.35
	Total current assets	168.79	151.68
	TOTAL ASSETS (I + II)	659.14	663.12
	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	995.68	995.68
	(b) Other Equity	(1,057.02)	(1,115.32)
	Total equity	(61.34)	(119.64)
II	Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	400.00	500.00
	(b) Provisions	24.41	20.05
	Total non-current liabilities	424.41	520.05
III	Current liabilities		
	(a) Financial liabilities		
	(i) Trade payables		
	(a)Total outstanding dues of micro and small enterprises	2.48	2.48
	(b)Total outstanding dues of creditors other than micro and small enterprises	247.98	228.58
	(ii) Other financial liabilities	16.04	17.58
	(b) Other current liabilities	3.83	4.95
	(c) Provisions	7.89	7.89
	(d) Current tax liabilities (net)	17.85	1.23
	Total current liabilities	296.07	262.71
	Total liabilities (II + III)	720.48	782.76
	TOTAL EQUITY AND LIABILITIES (I + II + III)	659.14	663.12

For MEDINOVA DIAGNOSTIC SERVICES LIMITED

SUNIL
CHANDRA
KONDAPALLY
Y

Digitally signed by
SUNIL CHANDRA
KONDAPALLY
Date: 2025.11.03
11:29:13 +05'30'

Sunil Chandra Kondapally

Managing Director

DIN 01409332

Place: Hyderabad

Date: 03 November 2025

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Unaudited Standalone Statement of Cash Flows

		(Rs. in Lakhs)	
Particulars		Half Year ended September 30, 2025 (Unaudited)	Half Year ended September 30, 2024 (Unaudited)
A	Cash flow from operating activities		
	Profit before tax	87.74	56.19
	<i>Adjustments for:</i>		
	Depreciation and amortisation expenses	6.77	6.74
	Net (gain)/loss on sale of property, plant and equipment	-	3.20
	Interest income	(0.39)	(0.29)
	Finance costs	22.36	25.07
	Operating profit before changes in assets and liabilities	116.48	90.91
	Changes in working capital:		
	Decrease/(Increase) in trade receivables	7.60	(9.75)
	Decrease/(Increase) in inventories	2.09	(0.28)
	Decrease/(Increase) in other financial assets	(0.29)	(2.00)
	Decrease/(Increase) in other tax assets	(17.88)	(2.00)
	Decrease/(Increase) in other current assets	(0.98)	(0.10)
	Increase/(Decrease) in trade payables	19.40	10.73
	Increase/(Decrease) in provisions and other liabilities	18.41	(4.77)
	Increase/(Decrease) in other financial liabilities	(1.54)	(0.87)
	Cash generated from operations	143.29	81.87
	Income tax paid	-	(9.00)
	Net cash from operating activities	143.29	72.87
B	Cash flows from investing activities		
	Acquisition of property, plant and equipment	(1.04)	(22.22)
	Proceeds from sale of property, plant and equipment	-	2.75
	Interest received	0.30	-
	Net cash used in investing activities	(0.74)	(19.47)
C	Cash flows from financing activities		
	Proceeds of/(Repayment of) loan from holding company	(100.00)	-
	Interest paid	(22.36)	(26.52)
	Net cash from/(used in) financing activities	(122.36)	(26.52)
	Net increase/ (decrease) in cash and cash equivalents (A + B + C)	20.19	26.88
	Cash and cash equivalents at the beginning of the year	88.08	61.20
	Cash and cash equivalents at end of the year	108.27	88.08
Note:			
(a) The above Statement of Cash Flow has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - Statement of Cash Flows.			
(b) Cash and cash equivalents mentioned above comprise the following:			
		As at	As at
		September 30, 2025	September 30, 2024
	Cash on hand	1.37	2.26
	Balances with banks		
	- in current accounts	106.90	85.82
	Total cash and cash equivalents	108.27	88.08
For MEDINOVA DIAGNOSTIC SERVICES LIMITED			
Place: Hyderabad		SUNIL CHANDRA KONDAPALLY	Digitally signed by SUNIL CHANDRA KONDAPALLY Date: 2025.11.03 11:29:36 +05'30'
Date: 03 November 2025		Sunil Chandra Kondapally	
		Managing Director	
		DIN 01409332	

M.ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Consolidated Unaudited Financial Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

**Review Report to the Board of Directors
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Medinova Diagnostic Services Limited ("the Holding Company") and its wholly owned subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th September, 2025 and year to date results for the period 1st April, 2025 to 30th September, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the wholly owned subsidiary, Medinova Millenium MRI Services LLP.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

6. The Scheme of Amalgamation of the Company, with and into the Holding Company "Vijaya Diagnostic Centre Limited" with effect from 01st April, 2024, was approved by its shareholders on 25th April, 2025. The Scheme was also approved by the Hon'ble National Company Law Tribunal, Hyderabad vide its order dated 13th October, 2025. The Scheme will be effective upon filing of the certified true copy of the NCLT order with the Registrar of Companies, Hyderabad.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

MADHURI Digitally signed by
CHIMALGI MADHURI CHIMALGI
Date: 2025.11.03
11:46:07 +05'30'

Madhuri Chimalgi
Partner
M No: 235955

UDIN: 25235955BOGRSX5845

Place: Secunderabad
Date: 3rd November, 2025

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2025

Sl. No.	Particulars	Quarter Ended			Half Year Ended		(Rs. in Lakhs) Year Ended
		30.09.2025 (Unaudited)	30.06.2025 (Unaudited)	30.09.2024 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
1	Income:						
	(a) Revenue from Operations	249.68	272.13	256.08	521.81	505.13	981.29
	(b) Other Income	3.04	5.63	2.55	8.67	4.22	14.56
	Total Income	252.72	277.76	258.63	530.48	509.35	995.85
2	Expenses						
	(a) Cost of Materials Consumed	14.58	14.50	17.66	29.08	38.20	64.32
	(b) Employee Benefits Expense	42.78	42.44	45.94	85.22	93.09	182.60
	(c) Testing Fees	22.47	22.06	19.84	44.53	34.86	74.44
	(d) Finance Costs	10.51	11.85	12.60	22.36	25.07	50.00
	(e) Depreciation	3.36	3.51	3.61	6.87	6.87	14.47
	(f) Other Expenses	77.84	87.44	92.60	165.28	189.43	360.36
	Total Expenses	171.54	181.80	192.25	353.34	387.52	746.19
3	Profit before Tax	81.18	95.96	66.38	177.14	121.83	249.66
4	Tax Expense						
	(a) Current Tax	23.22	27.63	15.67	50.85	25.12	47.55
	(b) Earlier Year's Tax	-	-	-	-	-	0.42
	(c) Deferred Tax	6.48	2.25	0.95	8.73	4.71	12.02
	Total tax expense	29.70	29.88	16.62	59.58	29.83	59.99
5	Profit/Loss for the period (3-4)	51.48	66.08	49.76	117.56	92.00	189.67
6	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss :						
	i) Remeasurement of defined benefit plans	(0.72)	(0.73)	0.00	(1.45)	0.00	(2.64)
	ii) Income tax relating to above	0.18	0.18	0.00	0.36	0.00	0.67
7	Total Comprehensive Income for the period (5+6)	50.94	65.53	49.76	116.47	92.00	187.70
	Net Profit attributable to:						
	(a) Owners of the Company	51.48	66.08	49.76	117.56	92.00	189.67
	(b) Non Controlling Interest	-	-	-	-	-	-
	Other Comprehensive Income attributable to:						
	(a) Owners of the Company	(0.54)	(0.55)	-	(1.09)	-	(1.98)
	(b) Non Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income attributable to:						
	(a) Owners of the Company	50.94	65.53	49.76	116.47	92.00	187.69
	(b) Non Controlling Interest	-	-	-	-	-	-
8	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)						
	a) Basic (Rs.)	0.52	0.66	0.50	1.18	0.92	1.89
	b) Diluted (Rs.)	0.52	0.66	0.50	1.18	0.92	1.89

Notes

1. The above Consolidated financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 03 November 2025. The Statutory Auditors of the Company have expressed an unmodified audit opinion on these results
3. The above results include the results of the wholly owned subsidiary, Medinova Millennium MRI Services LLP.
4. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
5. The Group has prepared consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".
6. The Board of Directors of the Company, at its meeting held on 26 June 2024, approved a Scheme of Amalgamation ("the Scheme") under which Medinova Diagnostic Services Limited ("Transferor Company") would get merged with Vijaya Diagnostic Centre Limited ("Transferee Company") with effect from 01 April 2024 ("the Appointed Date"), pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and the rules made thereunder. The Scheme was approved by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), vide its order dated 13 October 2025. The Scheme will be effective upon filing of the certified true copy of the NCLT order with the Registrar of Companies, Hyderabad. Upon the scheme being effective the transferor company shall stand automatically dissolved without winding-up and the offices of the Directors, Key Managerial Personnel and Statutory Auditors will stand vacated.

Place: Hyderabad
Date : 03 November 2025

For Medinova Diagnostic Services Limited

SUNIL
CHANDRA
KONDAPALLY
KONDAPALLY
Sunil Chandra Kondapally
Managing Director
DIN 01409332

Digitally signed by
SUNIL CHANDRA
KONDAPALLY
Date: 2025.11.03
11:26:34 +05'30'

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Unaudited Consolidated Balance Sheet as at September 30, 2025

		(Rs. in Lakhs)	
SI	Particulars	As at September 30, 2025	As at March 31, 2025
No.		(Unaudited)	(Audited)
	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	186.13	191.06
	(b) Intangible assets	1.78	2.68
	(c) Financial assets		
	(i) Other financial assets	24.98	30.22
	(d) Deferred tax assets, (net)	27.61	35.97
	(e) Non-current tax assets, (net)	9.70	11.89
	Total non-current assets	250.20	271.82
II	Current assets		
	(a) Inventories	10.10	14.98
	(b) Financial assets		
	(i) Investments	227.84	151.25
	(ii) Trade receivables	47.43	54.57
	(iii) Cash and cash equivalents	213.82	190.69
	(iv) Other financial assets	6.54	4.90
	(c) Other current assets	6.04	4.76
	Total current assets	511.77	421.15
	TOTAL ASSETS (I + II)	761.97	692.97
	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	995.68	995.68
	(b) Other equity	(1,004.01)	(1,120.47)
	Total equity	(8.33)	(124.79)
	Liabilities		
II	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	400.00	500.00
	(b) Provisions	24.41	20.05
	Total non-current liabilities	424.41	520.05
	Current liabilities		
	(a) Financial liabilities		
	(i) Trade payables		
	(a) Total outstanding dues of micro and small enterprises	2.48	3.31
	(b) Total outstanding dues of creditors other than micro and small enterprises	245.81	225.16
	(ii) Other financial liabilities	17.16	19.02
	(b) Other current liabilities	4.12	5.42
	(c) Provisions	43.24	43.07
	(d) Current Tax liabilities	33.08	1.73
	Total current liabilities	345.89	297.71
	Total liabilities (II + III)	770.30	817.76
	TOTAL EQUITY AND LIABILITIES (I + II + III)	761.97	692.97

For MEDINOVA DIAGNOSTIC SERVICES LIMITEI

SUNIL CHANDRA
KONDAPALLY

Digitally signed by SUNIL
CHANDRA KONDAPALLY
Date: 2025.11.03 11:27:03
+05'30'

Sunil Chandra Kondapally
Managing Director
DIN 01409332

Place: Hyderabad
Date : 03 November 2025

MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Unaudited Consolidated Statement of Cash Flows

(Rs. in Lakhs)

	Half Year ended September 30, 2025	Half Year ended September 30, 2024
A. Cash flow from operating activities		
Profit before tax	177.14	121.83
<i>Adjustments for:</i>		
Depreciation expense	6.87	6.87
Net gain on sale of property, plant and equipment	-	3.20
Interest income	(1.97)	(3.67)
Finance costs	22.36	25.07
Fair value gain on investments measured at FVTPL	(6.59)	-
Operating profit before changes in assets and liabilities	197.81	153.30
Changes in working capital:		
(Increase)/ decrease in trade receivables	7.14	(14.55)
(Increase)/ decrease in inventories	4.88	(1.30)
(Increase)/ decrease in other financial assets	3.67	(4.73)
Decrease/(Increase) in other tax assets	(48.66)	(3.90)
Decrease/(Increase) in other current assets	(1.28)	(0.29)
Increase/(decrease) in trade payables	19.82	9.18
Increase/(decrease) in provisions and other liabilities	34.43	(4.14)
Increase/(decrease) in other financial liabilities	(3.16)	4.63
Cash generated from operations	214.65	138.20
Income tax paid	-	(22.00)
Net cash generated from operating activities (A)	214.65	116.20
B. Cash flows from investing activities		
Acquisition of property, plant and equipment	(1.04)	(39.88)
Proceeds from sale of property, plant and equipment	-	2.75
Investment made in liquid mutual funds	(70.00)	
Interest received	1.88	4.70
Net cash used in investing activities (B)	(69.16)	(32.43)
C. Cash flows from financing activities		
Proceeds of/(Repayment of) loan from holding company	(100.00)	-
Interest paid	(22.36)	(26.52)
Net cash used in financing activities	(122.36)	(26.52)
Net increase/(decrease) in cash and cash equivalents (A + B + C)	23.13	57.25
Cash and cash equivalents at the beginning of the year	190.69	191.49
Cash and cash equivalents at end of the year	213.82	248.74
Note:		
(a) The above Statement of Cash Flows has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - Statement of Cash Flows.		
(b) Cash and cash equivalents mentioned above comprise the following:		
	As at September 30, 2025	As at September 30, 2024
Cash on hand	1.37	1.31
Balances with banks		
- in current accounts	212.45	80.92
- in deposit accounts	-	166.51
Total cash and cash equivalents	213.82	248.74
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> <p>Place: Hyderabad</p> <p>Date : 03 November 2025</p> </div> <div align="center"> <p>For MEDINOVA DIAGNOSTIC SERVICES LIMITED</p> <p>SUNIL CHANDRA KONDAPALLY Sunil Chandra Kondapally Managing Director DIN 01409332</p> </div> <div align="right"> <p><small>Digitally signed by SUNIL CHANDRA KONDAPALLY Date: 2025.11.03 11:27:27 +05'30'</small></p> </div> </div>		